NasdaqCM - Nasdaq Real Time Price • USD
Oncolytics Biotech Inc. (ONCY)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 7:53 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | -0.08 | -0.08 | -0.3 | -0.33 |
| Low Estimate | -0.09 | -0.08 | -0.33 | -0.4 |
| High Estimate | -0.07 | -0.07 | -0.26 | -0.28 |
| Year Ago EPS | -0.08 | -0.09 | -0.3 | -0.3 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -- | -- | 1.46M | 9.9M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | 4.38M | 29.7M |
| Year Ago Sales | -- | -- | -- | 1.46M |
| Sales Growth (year/est) | -- | -- | -- | 578.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.1 | -0.08 | -0.08 | -0.11 |
| EPS Actual | -0.08 | -0.09 | -0.1 | -0.04 |
| Difference | 0.02 | -0.01 | -0.02 | 0.07 |
| Surprise % | 20.00% | -12.50% | -25.00% | 63.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.08 | -0.08 | -0.3 | -0.33 |
| 7 Days Ago | -0.08 | -0.07 | -0.3 | -0.33 |
| 30 Days Ago | -0.08 | -0.08 | -0.3 | -0.33 |
| 60 Days Ago | -0.12 | -0.11 | -0.43 | -0.4 |
| 90 Days Ago | -0.12 | -0.11 | -0.43 | -0.4 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ONCY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 0.00% | -- | -- | 1.50% |
| Next Qtr. | 11.10% | -- | -- | 11.40% |
| Current Year | 0.00% | -- | -- | 5.20% |
| Next Year | -10.00% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Raymond James: Outperform | 4/4/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/14/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/19/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/4/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/13/2023 |
Related Tickers
OCUP Ocuphire Pharma, Inc.
1.5300
-0.65%
MBRX Moleculin Biotech, Inc.
4.3500
-5.43%
PGEN Precigen, Inc.
1.4200
+1.43%
MIST Milestone Pharmaceuticals Inc.
1.6600
-2.35%
AGEN Agenus Inc.
7.42
+14.86%
CNSP CNS Pharmaceuticals, Inc.
0.2140
+1.90%
NKTX Nkarta, Inc.
7.17
-5.16%
CYCC Cyclacel Pharmaceuticals, Inc.
2.2999
+28.49%
TRAW Traws Pharma, Inc.
0.6414
-3.62%
XERS Xeris Biopharma Holdings, Inc.
1.7600
-1.12%